Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine

Vaccine. 2023 Feb 24;41(9):1545-1549. doi: 10.1016/j.vaccine.2023.01.049. Epub 2023 Jan 31.

Abstract

Longitudinal data on the immune response from the first dose to several months after the third dose of COVID-19 vaccine are limited. We analyzed the immune response in 406 Japanese healthcare workers who received at least three doses of vaccine. The geometric mean anti-receptor binding domain IgG antibody titers and antigen-stimulated T-cell interferon-gamma levels after 6 months after receiving a third dose were similar to those 8 weeks after receiving a second dose. Humoral and cellular immunity induced by the third dose was more durable than that induced by the second dose. UMIN Clinical Trials Registry ID: UMIN000043340.

Keywords: Antibody; BNT162b2; COVID-19 vaccine; Cellular immunity; Third dose.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine* / immunology
  • COVID-19* / prevention & control
  • East Asian People
  • Health Personnel
  • Humans
  • Immunity, Cellular*
  • Immunity, Humoral*

Substances

  • Antibodies, Viral
  • BNT162 Vaccine

Associated data

  • UMIN-CTR/UMIN000043340